← Leaderboards
Elena Shagisultanova
University Of Colorado Denver
$1,196,358
Attributed
$1,196,358
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $246K · FY2019–23$250K$187.5K$125K$62.5K$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$1,196,358 · 1
By mechanism
K08$1,196,358 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Diana M. Cittelly$3,958,321
- Wendy B Macklin$14,857,442
- Nanette F. Santoro$20,812,570
- Steven M Anderson$12,033,077
- Ruben Alvero$426,867
Others in their field
Other Emerging Leaders on “Adhesions”
- Brian Hess · Revbio, Inc.$10,684,188
- Gary Fanger · Rise Therapeutics, Llc$5,693,496
- Alice E White · Trustees Of Boston University$5,580,231
- Brendon M Baker · Trustees Of Boston University$5,580,231
- Steve Lim · University Of South Alabama$4,942,628
- Patrick R Secor · University Of Montana$4,394,600
Research focus
AdhesionsClinical ResearchApoptoticAromatase InhibitorsBag1 GeneChromosomal RearrangementBcl2 GeneBiological MarkersBiomarker DevelopmentBiomarker PanelBiomarker ValidationBiopsyAnimal ModelAcuteCancer CellCancer SubtypesCareer DevelopmentCd47 GeneCdk4 GeneCell LineCell ProliferationCessation Of LifeChemotherapyClinical Trials
Grant awards (5)
Discovering mechanisms of sensitivity and resistance to triple combination targeted therapy in HR+/HER2+ breast cancer$230,751
K08 · FY2023 · CA · contact PI
Discovering mechanisms of sensitivity and resistance to triple combination targeted therapy in HR+/HER2+ breast cancer$231,831
K08 · FY2022 · CA · contact PI
Discovering mechanisms of sensitivity and resistance to triple combination targeted therapy in HR+/HER2+ breast cancer$243,872
K08 · FY2021 · CA · contact PI
Discovering mechanisms of sensitivity and resistance to triple combination targeted therapy in HR+/HER2+ breast cancer$243,872
K08 · FY2020 · CA · contact PI
Discovering mechanisms of sensitivity and resistance to triple combination targeted therapy in HR+/HER2+ breast cancer$246,032
K08 · FY2019 · CA · contact PI